Details

Autor(en) / Beteiligte

• Lundgren, Jens D
• Grund, Birgit
• Barkauskas, Christina E
• Holland, Thomas L
• Gottlieb, Robert L
• Sandkovsky, Uriel
• Brown, Samuel M
• Knowlton, Kirk U
• Self, Wesley H
• Files, D Clark
• Jain, Mamta K
• Benfield, Thomas
• Bowdish, Michael E
• Leshnower, Bradley G
• Baker, Jason V
• Jensen, Jens-Ulrik
• Gardner, Edward M
• Ginde, Adit A
• Harris, Estelle S
• Johansen, Isik S
• Markowitz, Norman
• Matthay, Michael A
• Østergaard, Lars
• Chang, Christina C
• Davey, Victoria J
• Goodman, Anna
• Higgs, Elizabeth S
• Murray, Daniel D
• Murray, Thomas A
• Paredes, Roger
• Parmar, Mahesh K B
• Phillips, Andrew N
• Reilly, Cavan
• Sharma, Shweta
• Dewar, Robin L
• Teitelbaum, Marc
• Wentworth, Deborah
• Cao, Huyen
• Klekotka, Paul
• Babiker, Abdel G
• Gelijns, Annetine C
• Kan, Virginia L
• Polizzotto, Mark N
• Thompson, B Taylor
• Lane, H Clifford
• Neaton, James D

Titel

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

Ist Teil von

• The New England journal of medicine, 2021-03, Vol.384 (10), p.905-914

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In a platform trial involving patients hospitalized with Covid-19, among 314 patients who were also being treated with remdesivir, those who received the monoclonal antibody LY-CoV555 did not have better pulmonary function at day 5 than those who received placebo. The trial was stopped for futility.